AK112 in Advanced Non-Small Cell Lung Cancer

NCT05499390 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

398

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non-small-cell Lung Cancer

Interventions

DRUG: AK112
DRUG: Pembrolizumab

Sponsor

Akeso